Skip to main content
Equibles
LXRX logo

LXRX · Lexicon Pharmaceuticals, Inc. · Metrics

Track LXRX — free

Use LXRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LXRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.79 -0.03 (-1.65%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$796.97M
Shares
445.23M
Volume · Nov 13 1.89M Avg daily vol (3M) 2.62M

LXRX metrics

87 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.79
Market cap
$796.97M

Price action

23 metrics
Price change (1W)
+0.6%
Price change (30D)
+8.5%
Price change (3M)
-22.8%
Price change (6M)
-19.7%
Price change (YTD)
+55.7%
Price change (1Y)
+24.3%
Trailing year
Price change (5Y)
-64.9%
52-week high
$2.64
52-week low
$1.14
Change from 52-week high
-32.2%
Change from 52-week low
+57.0%
Annualized volatility
71.9%
Annualized volatility (3M)
57.7%
Implied volatility (30D)
113.5%
IV rank (1Y)
19.0
IV percentile (1Y)
54.3
Beta
1.0
RSI (14D)
58.2
Price vs SMA 50
+1.1%
Price vs SMA 200
-5.5%
Avg volume (3M)
2.62M
Relative volume
0.7
Average dollar volume
$5.03M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
445.23M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
17.3×
reciprocal yield 5.8%
EV / EBITDA
—
EV / EBIT
—
P / sales
20.7×
reciprocal yield 4.8%
P / book
4.9
reciprocal yield 20.6%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-7.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
57.3×
reciprocal yield 1.7%
EV / revenue historical average (5Y)
109.6×
reciprocal yield 0.9%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-05

Profitability

9 metrics
Gross margin
98.9%
Operating margin
-147.4%
Trailing 12 months
Net margin
-161.8%
Gross profit (TTM)
$38.11M
Operating profit (TTM)
−$56.81M
Net income (TTM)
−$62.35M
Trailing 12 months
Diluted EPS (TTM)
$-0.14
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.09
Gross profit per diluted share (TTM)
$0.09
Operating profit per diluted share (TTM)
$-0.14
EBITDA per diluted share (TTM)
$-0.14
Net income per diluted share (TTM)
$-0.15
Operating cash flow per diluted share (TTM)
$-0.12
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.14
Stock compensation per diluted share (TTM)
$0.03
Book value per share
$0.29

Growth

11 metrics
Revenue growth YoY
-20.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$38.54M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+22.4%
Year over year · more shares
Revenue CAGR (3Y)
+610.3%
Revenue CAGR (5Y)
+15.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-38.1%
Return on assets
-25.8%
Debt / equity
0.3
Current ratio
10.6
EBITDA (TTM)
−$56.39M
Free cash flow (TTM)
—
Quick ratio
10.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$131.31M
Latest balance sheet
Cash & equivalents
$44.08M
Total assets
$242.02M
Total debt
$51.89M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$49.23M
Capital expenditures (TTM)
—
R&D (TTM)
$57.72M
SG&A (TTM)
$37.20M
Stock compensation (TTM)
$12.63M
R&D / revenue
149.8%
Stock compensation / revenue
32.8%

Ownership (13F)

9 metrics
13F filers
150
13F filer change QoQ
+14
Institutional ownership
82.3%
Conviction holders (share of 13F filers)
0.7%
Crowding (high-turnover and private-fund holders)
8.7%
Private-fund adviser ownership
8.3%
Active holders' share change QoQ
-2.3%
Holder tenure
19.5
Price vs estimated holder cost
+68.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
6.0%

Short interest

3 metrics
Short interest
5.8%
Latest settlement · 14.0 days to cover
Days to cover
14.0d
Short-squeeze score
69 / 100

Insider activity

2 metrics
Net insider buying (90D)
$49,999
Insider-sentiment score
75 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1062822 CUSIP 528872302 13F (30d) 122 filings 108 filers Visit website Investor relations